Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO). Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
This development is significant for the pharmaceutical industry, as AI and automation are increasingly seen as critical to improving efficiency, reducing errors, and accelerating production timelines. Oncotelic’s platform could offer a competitive edge by enabling real-time monitoring and adaptive control of manufacturing processes, potentially lowering costs and improving compliance with regulatory standards. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, underscoring the innovative foundation of the technology.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. Beyond its internal pipeline, the company licenses and co-develops drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio. The PDAOAI platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
For more information, see the full press release at https://nnw.fm/j1n43 and the company’s newsroom at https://nnw.fm/OTLC.
